Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05118204 · ClinicalTrials.gov registry record · Phase 4
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
A Phase 4 study, sponsored by Montefiore Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT05118204 is a Phase 4 study that was terminated before completion, run by Montefiore Medical Center. The registered enrollment target is 23 participants.
The verdict
NCT05118204, a Phase 4 study, was terminated before completion, sponsored by Montefiore Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
Investigators will test a novel protocol for starting BUP (buprenorphine-naloxone) treatment. The BUP microdose induction protocol has participants start very low doses of BUP without stopping other opioids that they are taking. The treatment as usual (TAU) has participants stop other opioids and experience opioid withdrawal before starting BUP. Investigators propose to test BUP microdose inductions vs. TAU in a randomized controlled trial.
Interventions
- DRUG TAU
- DRUG BUP microdose induction
- BEHAVIORAL Linkage to outpatient BUP treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-09-29 |
| Est. Completion | 2025-04-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05118204
The ClinicalTrials.gov registry entry for NCT05118204 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which TAU is the first listed.
NCT05118204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05118204 about?
NCT05118204 is a clinical study titled "Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization". Investigators will test a novel protocol for starting BUP (buprenorphine-naloxone) treatment. The BUP microdose induction protocol has participants start very low doses of BUP without stopping other opioids that they are taking. The treatment as usual (TAU) has participants stop other opioids and ex...
What is the current status of trial NCT05118204?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2022-09-29. Estimated completion is 2025-04-09.
What interventions are being tested in trial NCT05118204?
The interventions under investigation include: TAU (DRUG), BUP microdose induction (DRUG), Linkage to outpatient BUP treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT05118204?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.